Printer Friendly
The Free Library
19,585,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Biopure Announces First Quarter 2004 Conference Call and Webcast.


Business Editors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 12, 2004

Biopure Corporation (Nasdaq:BPUR BPUR Biopure Corporation (stock symbol) ) will announce its financial results for the first fiscal quarter ended January 31, 2004, on Thursday, February 19, 2004, after the market closes. Following the announcement, Biopure President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  Thomas A. Moore will host a conference call at 4:30 p.m. Eastern Standard Time (EST EST electroshock therapy.

EST
abbr.
electroshock therapy
). The dial-in numbers for investors are 1-877-888-4605 (US/Canada) and 1-416-695-5261 (International).

A live audio webcast of the conference call will be available from the investor section of Biopure's web site at www.biopure.com and will be archived for 30 days. The webcast can also be heard by individual investors at www.companyboardroom.com and by institutional investors who subscribe to Verb 1. subscribe to - receive or obtain regularly; "We take the Times every day"
subscribe, take

buy, purchase - obtain by purchase; acquire by means of a financial transaction; "The family purchased a new car"; "The conglomerate acquired a new company";
 StreetEvents at www.streetevents.com.

An audio replay of the conference call will be available from approximately 7:30 p.m. EST, February 19, 2004, until midnight on February 26, 2004. To access the replay, dial 1-800-293-5765 (US/Canada) or 1-416-695-6379 (International/Local) and PIN number 0886.

Biopure Corporation

Biopure Corporation, headquartered in Cambridge, Mass., is a leading developer, manufacturer and marketer of oxygen therapeutics, a new class of pharmaceuticals that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) (hemoglobin glutamer - 250 (bovine)) is approved in South Africa for the treatment of adult surgical patients who are acutely anemic and for the purpose of eliminating, delaying or reducing the need for allogenic allogenic /al·lo·gen·ic/ (-jen´ik) allogeneic.
allogenic,
adj from individuals of the same species. Tissue transplanted from one person to another is said to be allogenic.
 red blood cell red blood cell: see blood.  transfusion in these patients. Biopure's veterinary product Oxyglobin(R) (hemoglobin glutamer - 200 (bovine)), the only oxygen therapeutic approved by the U.S. Food Drug and Administration and the European Commission, is indicated for the treatment of anemia in dogs.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Feb 12, 2004
Words:280
Previous Article:Western Wireless Announces Fourth Quarter and Full Year 2003 Financial Results.
Next Article:EuroZinc Mining Corporation: Bid for Neves Corvo Opened by Jury.
Topics:



Related Articles
FAKE BLOOD Ready to Flow.
World's First Oxygen Therapeutic for Human Use Approved in South Africa to Treat Acute Anemia in Surgery Patients; Biopure to Hold Conference Call...
Biopure Announces Fourth Quarter 2002 Conference Call and Webcast.
Biopure Announces First Quarter 2003 Conference Call and Webcast.
Biopure Announces Second Quarter 2003 Conference Call and Webcast.
Biopure Announces Third Quarter 2003 Conference Call and Webcast.
Biopure Announces Fourth Quarter 2003 Conference Call and Webcast.
BRIEFCASE SEC TO SUE MAKER OF BLOOD PRODUCT.
Stull, Stull & Brody Announces Class Action on Behalf of Biopure Share Purchasers.
Bernstein Litowitz Berger & Grossmann LLP Announces Class Action Lawsuit Against Biopure Corporation on Behalf of Investors.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles